481.75
+5.15
+(1.08%)
As of 10:01:55 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 24 | 15 | 32 | 34 |
| Avg. Estimate | 4.14B | 4.18B | 15.58B | 17.92B |
| Low Estimate | 4.1B | 4.09B | 15.51B | 17.51B |
| High Estimate | 4.24B | 4.27B | 15.67B | 18.25B |
| Year Ago Sales | 3.67B | 3.64B | 13.25B | 15.58B |
| Sales Growth (year/est) | 12.90% | 14.87% | 17.63% | 14.99% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 639.F | -- | -- | -- | -- |
| S&P 500 | 8.43% | 11.29% | 13.87% | 13.50% |
Upgrades & Downgrades
| Maintains | UBS: Buy to Buy | 1/15/2025 |
| Maintains | Keybanc: Overweight to Overweight | 1/10/2025 |
| Maintains | Goldman Sachs: Buy to Buy | 1/8/2025 |
| Maintains | Canaccord Genuity: Buy to Buy | 12/2/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 11/14/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 11/14/2024 |